CLVT stock forecast, quote, news & analysis
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare... Show more
Why Clarivate (CLVT) Stock Is Up +35.8% in the Last 30 Days
Key Takeaways
- Clarivate shares rose roughly 35.8% over the past 30 days, climbing from about $1.48 to near $2.01, a rebound from a 52-week low set in early October.
- The rally was driven by the completed $600 million sale of its Life Sciences & Healthcare segment, an earnings beat, and accelerating AI-related product momentum.
- Third-quarter adjusted diluted EPS of $0.21 topped the $0.18 consensus, while Intellectual Property annual contract value returned to growth for the first time in over three years.
- The stock's three-month trend remains volatile: shares slid from roughly $1.94 in early August to about $1.42–$1.45 in early October before the sharp recovery.
- Key risks include continued pressure on transactional revenue, a trimmed full-year growth outlook, and a still-elevated net debt load of roughly $4.2 billion.
- For deeper data on this ticker, explore Price Targets, Earnings, and Forecast pages.
- For automated trading insights, explore Tickeron's Trending AI Robots.
Clarivate (CLVT) Company Overview and Market Position
Clarivate Plc is a London-headquartered global provider of "transformative intelligence," delivering enriched data, analytics, workflow software, and expert services across two core segments: Academia & Government and Intellectual Property. Its well-known products include Web of Science, ProQuest, Derwent, CompuMark, and the IPfolio and Alma platforms. The company serves universities, research institutions, libraries, governments, funders, patent and trademark offices, and IP-intensive enterprises, with roughly 93% of its revenue recurring. Following the divestiture of its Life Sciences & Healthcare business, Clarivate operates as a more focused, subscription-first business with approximately $2 billion in annual revenue.
Clarivate (CLVT) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, Clarivate shares advanced roughly 35.8%, rising from a closing price near $1.48 in early October to about $2.01. The gain came on the back of a steep late-period rally, with the shares jumping sharply on the day of the company's third-quarter earnings release in early November.
The broader three-month picture tells a more volatile story. The stock began the quarter near $1.94, slid through September under pressure from leverage concerns and subdued organic-growth expectations, and touched the $1.42–$1.45 area in early October — near the low end of its 52-week range of roughly $1.42 to $3.87. The subsequent recovery left the shares up only about 4% over the full quarter, masking a deep drawdown and a sharp rebound.
What Drove CLVT Stock Price in the Last 30 Days
Several catalysts converged to fuel the rally. On October 6, Clarivate completed the $600 million sale of its Life Sciences & Healthcare segment to Altaris, LLC, simplifying the portfolio and earmarking proceeds for debt reduction. The transaction reinforced the company's transformation into a focused, recurring-revenue business.
The biggest single catalyst was the third-quarter report in early November. Adjusted diluted EPS of $0.21 beat the $0.18 consensus estimate, and management highlighted that Intellectual Property annual contract value turned positive for the first time in more than three years. Recurring organic revenue grew 1.3%, its strongest rate in over a year, while adjusted EBITDA margin expanded to 45.3% from 41.9% a year earlier.
AI-related momentum also supported sentiment. The Web of Science Research Intelligence platform surpassed 100 institutional wins across 25 countries, and the company's IPOne agentic-AI platform reported an active sales pipeline of more than 150 customers ahead of its early-adopter launch. A co-development partnership announced with intellectual property law firm Sterne Kessler to build AI-enhanced patent workflow tools added further validation of the AI strategy.
What Drove CLVT Stock Performance Over the Last Quarter
The quarterly trend reflects a company in transition. Through August and September, the stock was pressured by a heavy debt burden, a wind-down of lower-margin businesses, and cautious expectations for organic growth. The announcement and completion of the Life Sciences & Healthcare divestiture — announced in July and closed ahead of schedule in October — represented the quarter's defining strategic event.
As the divestiture closed and the company reported improving recurring-revenue metrics, accelerating AI adoption, and progress toward roughly $875 million in full-year debt reduction, investor sentiment shifted. The resulting rebound highlights a market that increasingly credits Clarivate's repositioning, even as reported revenue remains constrained by disposals and weaker transactional volumes.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots drawn from a broader universe of hundreds of bots that trade thousands of tickers. Only the top-performing and most relevant bots appear in this section, giving users a focused view of strategies that are currently resonating with market conditions. The bots vary widely in strategy, timeframe, and performance metrics, so investors can evaluate approaches that match different risk profiles and holding periods. Exploring the page offers a practical way to see how algorithmic trading systems are positioned across the market.
CLVT Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors should monitor whether Clarivate sustains its recurring-revenue and ACV momentum, particularly the conversion of the IPOne and Web of Science Research Intelligence pipelines into contracted recurring revenue. Fourth-quarter and full-year guidance, including the outlook for roughly $320 million to $340 million in free cash flow, will be closely watched, as will progress on debt reduction and the trajectory toward a targeted net leverage of 3.5x to 3.6x by the end of 2027. Macroeconomic factors such as higher-education funding, foreign-exchange movements, and broader software-sector sentiment could also influence performance. These considerations are informational and should not be treated as financial advice.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CLVT in upward trend: 10-day moving average crossed above 50-day moving average on November 04, 2026
The 10-day moving average for CLVT crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on CLVT as a result. In 50 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.
The Moving Average Convergence Divergence (MACD) for CLVT just turned positive on October 13, 2026. Looking at past instances where CLVT's MACD turned positive, the stock continued to rise in 32 of 45 cases over the following month. The odds of a continued upward trend are 71%.
CLVT moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +10.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLVT advanced for three days, in 157 of 240 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
The Aroon Indicator entered an Uptrend today. In 69 of 120 cases where CLVT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLVT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
CLVT broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.330) is normal, around the industry mean (2.900). P/E Ratio (-4.500) is within average values for comparable stocks, (18.488). Projected Growth (PEG Ratio) (0.178) is also within normal values, averaging (2.284). Dividend Yield (0.000) settles around the average of (0.224) among similar stocks. P/S Ratio (0.504) is also within normal values, averaging (139.965).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. CLVT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 46 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLVT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of activated carbon and related products and systems
Industry InformationTechnologyServices